These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33432548)

  • 1. Type 2 Diabetes Mellitus and Vertebral Fracture Risk.
    Koromani F; Ghatan S; van Hoek M; Zillikens MC; Oei EHG; Rivadeneira F; Oei L
    Curr Osteoporos Rep; 2021 Feb; 19(1):50-57. PubMed ID: 33432548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.
    Anagnostis P; Paschou SA; Gkekas NN; Artzouchaltzi AM; Christou K; Stogiannou D; Vryonidou A; Potoupnis M; Goulis DG
    Endocrine; 2018 Jun; 60(3):373-383. PubMed ID: 29411304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of bone strength and factors associated with vertebral fracture in postmenopausal women with type 2 diabetes.
    Chen FP; Kuo SF; Lin YC; Fan CM; Chen JF
    Menopause; 2019 Feb; 26(2):182-188. PubMed ID: 30130285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus.
    Choi YJ; Ock SY; Jin Y; Lee JS; Kim SH; Chung Y-
    Osteoporos Int; 2018 Apr; 29(4):907-915. PubMed ID: 29322222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance between Prevalent Vertebral Fracture and Vertebral Strength Estimated by the Finite Element Method Based on Quantitative Computed Tomography in Patients with Type 2 Diabetes Mellitus.
    Kiyohara N; Yamamoto M; Sugimoto T
    PLoS One; 2015; 10(12):e0144496. PubMed ID: 26642210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Bone Mineral Density, Bone Turnover Markers, and Vertebral Fractures with All-Cause Mortality in Type 2 Diabetes Mellitus.
    Miyake H; Kanazawa I; Sugimoto T
    Calcif Tissue Int; 2018 Jan; 102(1):1-13. PubMed ID: 28965188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabecular Bone Score (TBS) and TBS-Adjusted Fracture Risk Assessment Tool are Potential Supplementary Tools for the Discrimination of Morphometric Vertebral Fractures in Postmenopausal Women With Type 2 Diabetes.
    Choi YJ; Ock SY; Chung YS
    J Clin Densitom; 2016 Oct; 19(4):507-514. PubMed ID: 27130256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of non-vertebral fractures in men with type 2 diabetes: A systematic review and meta-analysis of cohort studies.
    Gao Y; Chai F
    Exp Gerontol; 2021 Jul; 150():111378. PubMed ID: 33905874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of trabecular bone score and prevalent vertebral fractures in women with fragility fractures: a cross-sectional sub-study of NoFRACT.
    Borgen TT; Bjørnerem Å; Solberg LB; Andreasen C; Brunborg C; Stenbro MB; Hübschle LM; Figved W; Apalset EM; Gjertsen JE; Basso T; Lund I; Hansen AK; Stutzer JM; Dahl C; Nordsletten L; Frihagen F; Eriksen EF
    Osteoporos Int; 2020 Mar; 31(3):505-514. PubMed ID: 31754755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fracture risk assessment in postmenopausal women with diabetes: comparison between DeFRA and FRAX tools.
    Bonaccorsi G; Messina C; Cervellati C; Maietti E; Medini M; Rossini M; Massari L; Greco P
    Gynecol Endocrinol; 2018 May; 34(5):404-408. PubMed ID: 29172781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incident Fracture Risk in Type 2 Diabetic Postmenopausal Women in Mainland China: Peking Vertebral Fracture Study.
    Jiajue R; Qi X; Jiang Y; Wang Q; Wang W; Pei Y; Wang X; Huang W; Zheng X; Ning Z; Wang O; Li M; Xing X; Yu W; Xu L; Xia W
    Calcif Tissue Int; 2019 Nov; 105(5):466-475. PubMed ID: 31511960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Bone Mineral Density on the Incidence of Age-Related Vertebral Fragility Fracture.
    Lee J; Chang G; Kang H; Ham DW; Lee JS; Jung HS; Song KS
    J Korean Med Sci; 2020 May; 35(17):e116. PubMed ID: 32356418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment using serum insulin-like growth factor-I and bone mineral density is useful for detecting prevalent vertebral fractures in patients with type 2 diabetes mellitus.
    Kanazawa I; Notsu M; Miyake H; Tanaka K; Sugimoto T
    Osteoporos Int; 2018 Nov; 29(11):2527-2535. PubMed ID: 30030585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and risk factors of vertebral fractures in Korean patients with type 2 diabetes.
    Chung DJ; Choi HJ; Chung YS; Lim SK; Yang SO; Shin CS
    J Bone Miner Metab; 2013 Mar; 31(2):161-8. PubMed ID: 23076296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.